IDEXX Laboratories Inc IDXX

What the company does

IDEXX Laboratories Inc is a large-cap company in the Healthcare sector (Diagnostics & Research), with a market value of $44.1B, based in the USA.

It employs about 11,000 people and has been listed since Jun 21, 1991.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Cheap or expensive? priced in line with its group

Its price-to-earnings (P/E) is 39.8 versus 36.9 for the median of the Healthcare sector in our universe (25 companies) — priced in line with its group.

Revenue is growing 10% versus the same quarter last year.

On analysts' next-year forecasts the multiple drops to 31.4 — they expect higher earnings.

The average analyst price target is 698.00, 25% above the current price (their view, not ours).

The stock sits at 22% of its one-year range (0% = the low, 100% = the high).

The risks

• • The stock is more volatile than average (beta 1.5) — big daily moves both ways.
• • Quarterly report in 8 days (2026-11-02) — a day the stock can move a lot.

Strengths

• ✅ Profitable — 28 of every 100 dollars of revenue stays as profit.
• ✅ Generates free cash flow — profit becomes cash in the bank.
• ✅ Most analysts rate it buy (9 vs 1).

What changed this week

Over the past week the stock rose 0.0% (for comparison: S&P 500 -0.4%, sector ETF XLV +1.4%).

This week's news

• ResMed Set to Report Q1 Earnings: What's in the Cards for the Stock? finance.yahoo.com · 2026-10-23
  What the article says

  ResMed RMD is scheduled to release its first-quarter fiscal 2027 results on Oct. 29, after the closing bell. The renowned sleep health device maker posted adjusted earnings per share (EPS) of $2.95 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 1.72%. The company topped earnings… source ↗

• Here's How IDEXX Laboratories Is Placed Ahead of Q3 Earnings finance.yahoo.com · 2026-10-23
  What the article says

  IDEXX Laboratories, Inc. IDXX is set to release third-quarter 2026 results on Nov. 2, before the opening bell. In the last reported quarter, the company posted adjusted earnings per share (EPS) of $4.27, which surpassed the Zacks Consensus Estimate by 8.10%. IDEXX's earnings beat estimates in each of the trailing four… source ↗

• IDEXX Laboratories (IDXX) vs. ZTS and NEOG: Can Raised Guidance and Product Expansion Drive Further Earnings Growth? finance.yahoo.com · 2026-10-22
  What the article says

  Is IDXX a good stock to buy? We came across a bullish thesis on IDEXX Laboratories, Inc. on Astute Optics - US's Substack. In this article, we will summarize the bulls' thesis on IDXX. IDEXX Laboratories, Inc.'s share was trading at $553.48 as of October 21st 2026. IDXX's trailing and forward P/E were 36.65 and 31.45… source ↗

• Goldman Sachs Sees a Shift in the Stock Market — and Names 2 Stocks to Buy Now finance.yahoo.com · 2026-10-22
  What the article says

  Long-term stock market performance depends on more than economic growth, interest rates, and corporate earnings. Broader trends that develop over many years can also create investment opportunities, particularly for companies positioned to benefit from lasting changes in consumer behavior and business spending. These… source ↗

• Is This the Right Time to Hold EW Stock in Your Portfolio? finance.yahoo.com · 2026-10-22
  What the article says

  Edwards Lifesciences EW sees Transcatheter Mitral and Tricuspid Therapies ("TMTT") momentum, fueled by PASCAL, EVOQUE and SAPIEN M3, supported by clinical evidence and broader market access. The company's Transcatheter Aortic Valve Replacement ("TAVR") business continues to grow, with SAPIEN platform durability and… source ↗

• ILMN Q3 Earnings Preview: Strong Clinical Demand May Lift Performance finance.yahoo.com · 2026-10-22
  What the article says

  Illumina, Inc. ILMN is set to release third-quarter 2026 results on Oct. 29, after the closing bell. The company posted adjusted earnings per share (EPS) of $1.31 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 6.5%. Illumina beat earnings in each of the trailing four quarters, the… source ↗

What changed since last week

• New risk flag: earnings report coming up.